These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. The role of the toxicologic pathologist in the post-genomic era(#). Maronpot RR J Toxicol Pathol; 2013 Jun; 26(2):105-10. PubMed ID: 23914052 [TBL] [Abstract][Full Text] [Related]
5. Regulatory forum opinion piece: thresholds in toxicologic pathology. Long GG; Hardisty JF Toxicol Pathol; 2012 Oct; 40(7):1079-81. PubMed ID: 22585940 [TBL] [Abstract][Full Text] [Related]
6. Regulatory forum opinion piece: the role of the toxicologic pathologist in the postgenomic era: challenges and opportunities. Maronpot RR Toxicol Pathol; 2012 Oct; 40(7):1082-6. PubMed ID: 22585943 [TBL] [Abstract][Full Text] [Related]
7. Regulatory forum opinion piece: Tox21 and toxicologic pathology. Bucher JR Toxicol Pathol; 2013 Jan; 41(1):125-7. PubMed ID: 22692375 [TBL] [Abstract][Full Text] [Related]
8. The roles of the toxicologic pathologist in cancer research. Ward JM Toxicol Pathol; 2010 Jan; 38(1):39-42. PubMed ID: 19843952 [TBL] [Abstract][Full Text] [Related]
10. Nonclinical development of biopharmaceuticals. Baumann A Drug Discov Today; 2009 Dec; 14(23-24):1112-22. PubMed ID: 19853058 [TBL] [Abstract][Full Text] [Related]
11. Hazard identification and risk assessment for biologics targeting the immune system. Weir AB J Immunotoxicol; 2008 Jan; 5(1):3-10. PubMed ID: 18382852 [TBL] [Abstract][Full Text] [Related]
12. Biosimilars: impact of biologic product life cycle and European experience on the regulatory trajectory in the United States. Ahmed I; Kaspar B; Sharma U Clin Ther; 2012 Feb; 34(2):400-19. PubMed ID: 22244050 [TBL] [Abstract][Full Text] [Related]
13. Practical Strategies for Navigating Toxicologic Pathology in One's Early Career…and Beyond! Carreira V; Palanisamy G; Quist E; Nelson K; Fossey S; Zimmerman B; Ramaiah L; Schafer KA Toxicol Pathol; 2018 Dec; 46(8):1037-1048. PubMed ID: 30352538 [TBL] [Abstract][Full Text] [Related]
14. Opinion on Maintaining In-House GLP Status for Toxicologic Pathology in Pharmaceutical and (Agro)Chemical Development. Gauthier BE; Bach U; Chanut F; De Jonghe S; Groeters S; Mueller G; Palazzi X; Pohlmeyer-Esch G; Rinke M; Schorsch F Toxicol Pathol; 2022 Jan; 50(1):147-152. PubMed ID: 34433323 [TBL] [Abstract][Full Text] [Related]
15. The impact of network biology in pharmacology and toxicology. Panagiotou G; Taboureau O SAR QSAR Environ Res; 2012; 23(3-4):221-35. PubMed ID: 22352466 [TBL] [Abstract][Full Text] [Related]
16. Mechanisms of adverse drug reactions to biologics. Clarke JB Handb Exp Pharmacol; 2010; (196):453-74. PubMed ID: 20020272 [TBL] [Abstract][Full Text] [Related]
17. Anticancer Drug Development: The Way Forward. Connors T Oncologist; 1996; 1(3):180-181. PubMed ID: 10387985 [TBL] [Abstract][Full Text] [Related]
18. Regulatory forum opinion piece: what are pathology raw data? Leininger JR; Parker GA Toxicol Pathol; 2014; 42(3):469-71. PubMed ID: 23960165 [No Abstract] [Full Text] [Related]
19. [Peer review in toxicologic histopathology: its necessity, type and procedure]. Yoshitomi K J Toxicol Sci; 1998 May; 23 Suppl 1():1-9. PubMed ID: 9617732 [TBL] [Abstract][Full Text] [Related]
20. Regulatory Forum Opinion Piece*: An Experienced Pathologist Need Not Always Be Present at Necropsy for Small Molecule or Biotherapeutic Safety Studies. Nikula KJ Toxicol Pathol; 2016 Jan; 44(1):12-3. PubMed ID: 26656238 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]